Dummer R - Search Results

1

A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis.

Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, Ronai ZA. Claps G, et al. Among authors: dummer r. Cell Rep. 2016 May 31;15(9):1884-92. doi: 10.1016/j.celrep.2016.04.072. Epub 2016 May 19. Cell Rep. 2016. PMID: 27210757 Free PMC article.

2

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.

Zipser MC, Eichhoff OM, Widmer DS, Schlegel NC, Schoenewolf NL, Stuart D, Liu W, Gardner H, Smith PD, Nuciforo P, Dummer R, Hoek KS. Zipser MC, et al. Among authors: dummer r. Pigment Cell Melanoma Res. 2011 Apr;24(2):326-33. doi: 10.1111/j.1755-148X.2010.00823.x. Epub 2011 Jan 12. Pigment Cell Melanoma Res. 2011. PMID: 21176117

3

Sorafenib in melanoma.

Mangana J, Levesque MP, Karpova MB, Dummer R. Mangana J, et al. Among authors: dummer r. Expert Opin Investig Drugs. 2012 Apr;21(4):557-68. doi: 10.1517/13543784.2012.665872. Epub 2012 Mar 7. Expert Opin Investig Drugs. 2012. PMID: 22394203 Review.

4

Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy.

Rozati S, Naef L, Levesque MP, French LE, Dummer R. Rozati S, et al. Among authors: dummer r. J Immunother. 2013 Jan;36(1):52-6. doi: 10.1097/CJI.0b013e31827809c7. J Immunother. 2013. PMID: 23211621

5

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Das Thakur M, et al. Among authors: dummer r. Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9. Nature. 2013. PMID: 23302800 Free PMC article.

6

Melanoma immunotherapy: historical precedents, recent successes and future prospects.

Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. Raaijmakers MI, et al. Among authors: dummer r. Immunotherapy. 2013 Feb;5(2):169-82. doi: 10.2217/imt.12.162. Immunotherapy. 2013. PMID: 23413908 Review.

7

Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching.

Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MIG, Hemmi S, Dummer R, Levesque MP. Widmer DS, et al. Among authors: dummer r. J Invest Dermatol. 2013 Oct;133(10):2436-2443. doi: 10.1038/jid.2013.115. Epub 2013 Mar 8. J Invest Dermatol. 2013. PMID: 23474946 Free article.

8

SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis.

Cronin JC, Watkins-Chow DE, Incao A, Hasskamp JH, Schönewolf N, Aoude LG, Hayward NK, Bastian BC, Dummer R, Loftus SK, Pavan WJ. Cronin JC, et al. Among authors: dummer r. Cancer Res. 2013 Sep 15;73(18):5709-18. doi: 10.1158/0008-5472.CAN-12-4620. Epub 2013 Aug 1. Cancer Res. 2013. PMID: 23913827 Free PMC article.

9

Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Guenova E, et al. Among authors: dummer r. Expert Opin Investig Drugs. 2014 Apr;23(4):457-67. doi: 10.1517/13543784.2014.876407. Epub 2014 Jan 8. Expert Opin Investig Drugs. 2014. PMID: 24397291 Review.

10

To B-(RAF) or not to be.

Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP. Dummer R, et al. J Invest Dermatol. 2014 May;134(5):1200-1201. doi: 10.1038/jid.2014.62. J Invest Dermatol. 2014. PMID: 24732335 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

994 results

Search Page